SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 76.51 |
| Enterprise Value ($M) | 63.75 |
| Book Value ($M) | 103.10 |
| Book Value / Share | 1.66 |
| Price / Book | 0.74 |
| NCAV ($M) | 79.11 |
| NCAV / Share | 1.28 |
| Price / NCAV | 0.97 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.77 |
| Return on Assets (ROA) | -0.43 |
| Return on Equity (ROE) | -0.52 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 7.75 |
| Current Ratio | 7.75 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 111.87 |
| Assets | 135.87 |
| Liabilities | 32.76 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 16.15 |
| Operating Income | -65.57 |
| Net Income | -77.33 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -57.67 |
| Cash from Investing | 8.15 |
| Cash from Financing | 59.33 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Integrated Core Strategies (us) Llc | 4.00 | -21.27 | |
| 13D/A | Sullivan Lara | 11.21 | 13.86 | |
| 13G/A | Ridgeback Capital Investments L.P. | 0.60 | -91.73 | |
| 13G/A | Deep Track Capital, LP | 0.00 | -100.00 | |
| 13G | BlackRock, Inc. | 5.60 | ||
| 13G/A | Laurion Capital Management LP | 6.15 | 14.36 | |
| 13G/A | Bayer World Investments B.V. | 4.70 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| License Agreement with Biosion USA, Inc. | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 70,570 | 445,308 | 15.85 | |
| 66,803 | 282,901 | 23.61 | |
| 189,833 | 543,990 | 34.90 | |
| 138,813 | 535,098 | 25.94 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PRLD – Prelude Therapeutics Incorporated | PRTA – Prothena Corporation plc |
| PTCT – PTC Therapeutics, Inc. | QDEL – QuidelOrtho Corporation |
| QNCX – Quince Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io